[Fundamental and clinical studies of imipenem/cilastatin sodium in the field of obstetrics and gynecology].
Fundamental and clinical studies of imipenem/cilastatin sodium (MK-0787/MK-0791), a new carbapenem antibiotic, were carried out. The results obtained were summarized below. At a dose of 500 mg/500 mg, the penetration of MK-0787/MK-0791 into internal genital organs was good. The penetration of MK-0787/MK-0791 into pelvic dead space exudate was also good. Clinical results obtained were good in 4 patients and poor in 1, with an efficacy rate of 80%. No side effects were observed, but 1 patient showed slight elevations of GOT, GPT, Al-P and LDH. From these results, MK-0787/MK-0791 appeared to be a useful drug for the treatment of various infections in the field of obstetrics and gynecology.
Horii
T
T
Noda
K
K
D000328:Adult; D000368:Aged; D001424:Bacterial Infections / Q000188:drug therapy; D015377:Cilastatin; D003521:Cyclopropanes / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use; D004150:Dipeptidases / Q000037:antagonists & inhibitors*; D004338:Drug Combinations; D005260:Female; D005831:Genital Diseases, Female / Q000188:drug therapy; D005836:Genitalia, Female / Q000378:metabolism; D006801:Humans; D015378:Imipenem; D007262:Infusions, Intravenous; D008875:Middle Aged; D013845:Thienamycins / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use
D003521:Cyclopropanes; D004338:Drug Combinations; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D004150:Dipeptidases